Astrazeneca (AZN) Non-Current Debt (2009 - 2026)

Astrazeneca (AZN) has reported Non-Current Debt for 18 consecutive years, with -$24.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Debt rose 8.38% year-over-year to -$24.5 billion; the TTM figure through Mar 2026 stood at -$24.5 billion (up 8.38% YoY), while the FY2025 annual figure was -$24.7 billion, down 193.24% from the prior year.
• Non-Current Debt came in at -$24.5 billion for Q1 2026 at Astrazeneca, up from -$24.7 billion in the prior quarter.
• The five-year high for Non-Current Debt was $26.5 billion in Q4 2024, with the low at -$28.9 billion in Q3 2024.
• Average Non-Current Debt over 5 years is -$16.9 billion, with a median of -$24.7 billion recorded in 2025.
• Across the five-year window, Non-Current Debt increased 18.52% in 2024 and plunged 193.24% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $23.0 billion in 2022, then slipped by 2.61% to $22.4 billion in 2023, then gained by 18.52% to $26.5 billion in 2024, then slumped by 193.24% to -$24.7 billion in 2025, then advanced by 1.06% to -$24.5 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered -$24.5 billion, -$24.7 billion, and -$24.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.